Our findings show that EVs preferentially accumulate in the liver, where they suppress platelet‐derived growth factor B (PDGFB) via miR‐31‐5p, effectively impeding NAFLD progression by reducing fibrosis, inflammation and steatosis. Here, PDGFB is linked to metabolic dysfunction-associated steatotic liver disease.